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Background/objectives: Epicardial adipose tissue (EAT) reportedly secretes various adipokines that evoke insulin
resistance in patients with obesity ormetabolic syndrome. However, it remains unclearwhether EAT also plays a
role in the development of insulin resistance in lean subjects. The purpose of this study was to investigate the
impact of EAT volume on the presence of insulin resistance and coronary artery disease in non-obese subjects
without metabolic syndrome.
Methods:Weprospectively studied 624 consecutive patients who underwentmultidetector computed tomogra-
phy (MDCT) andmeasured EAT volume between January 2009 and June 2011. Obesitywas deﬁned as bodymass
index≥25kg/m2, andmetabolic syndromewasdeﬁned according to theNational Cholesterol Education Program
Adult Treatment Panel III criteria. After we excluded 385 patients with obesity or metabolic syndrome, 239
patients were enrolled in the present study.
Results: There were 102 (42.7%) subjects with insulin resistance (homeostasis model assessment ratio
[HOMA-R] N2.5) and 88 (36.8%) subjects with coronary artery disease. After adjusting for age, gender, and
bodymass index, increased EAT volume (≥35mlmean EAT volume) was independently associatedwith insulin
resistance (odds ratio 2.6, 95% conﬁdence interval 1.5–4.8). Furthermore, increased EAT volumewas also associ-
ated with coronary artery disease (odds ratio 1.9, 95% conﬁdence interval 1.0–3.6) after adjustment of age, gen-
der, body mass index, and the presence of insulin resistance.
Conclusion: Increased EAT volume may play a key role in the development of insulin resistance and coronary
artery disease, even in non-obese subjects without metabolic syndrome.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
The prevalence rates of obesity and overabundance of visceral fat are
increasing in developed countries [1]. It is obvious that obesity and in-
creased visceral fat are associated with impaired glucose tolerance and
the development of metabolic syndrome [2,3], which is a cluster of
risk factors for coronary artery disease [4]. Abdominal visceral fat can
produce large quantities of various adipokines that are strongly associ-
ated with coronary artery disease development [5]. Although the prev-
alence of obesity is still markedly lower in Japan compared to WesternPulmonology, and Nephrology,
hi, Yamagata 990-9585, Japan.
. Watanabe).
liability and freedom from bias
. This is an open access article undercountries (bodymass index≥25 kg/m2, 28% inmale and 22% in female;
≥30 kg/m2, 2.9% in male and 3.4% in female), the Japanese prevalence
rates of obesity and obesity-linked diseases have recently increased
[6–9].
Because epicardial adipose tissue (EAT) surrounding the heart is
adjacent tomajor coronary arteries, EAT is thought to be a source of sev-
eral inﬂammatory mediators involved in the development of coronary
artery disease [10,11]. Increased EAT volume and high levels of inﬂam-
matory mediators are signiﬁcantly related to insulin resistance and
coronary artery disease in obese subjects or patients with metabolic
syndrome [11,12]. We previously reported that high EAT volume was
associated with coronary artery disease in both obese and non-obese
patients [13]. A recent study described that insulin resistance is increas-
ingly prevalent among Japanese subjects without obvious obesity [14].
However, little is known about the pathological role of EAT in subjects
without obesity or metabolic syndrome.the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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EAT volume on the presence of insulin resistance and coronary artery
disease in non-obese subjects without metabolic syndrome.
2. Methods
2.1. Study population
We performed multi-detector row computed tomography (MDCT)
in 624 consecutive patients at the Yamagata University Hospital be-
tween September 2009 and October 2011. We excluded 82 patients
who had metabolic syndrome, 189 patients with obesity, and 115
patients without fasting insulin level data. The remaining 239 patients
were included in the present study (Fig. 1). All subjects provided writ-
ten informed consent prior to their participation, and the protocol was
approved by the institution's Human Investigation Committee. The pro-
cedures were performed in accordance with the Helsinki Declaration.
2.2. Deﬁnition of metabolic syndrome
Height and body weight were measured, and venous blood samples
were collected beforeMDCT.We deﬁnedmetabolic syndrome according
to the National Cholesterol Education Program Adult Treatment Panel III
criteria [15]. We modiﬁed these criteria for abdominal obesity by using
body mass index≥25 kg/m2 in place of waist circumference [16]. Meta-
bolic syndrome requires at least three of the following ﬁve criteria: body
mass index≥25 kg/m2, elevated triglyceride≥150 mg/dl, reduced high-
density lipoprotein cholesterol (HDLc) b40 mg/dl inmen and b50 mg/dl
in women, elevated fasting plasma glucose ≥110 mg/dl or previously
diagnosed diabetes mellitus, elevated blood pressure (systolic blood
pressure ≥130 mm Hg, and/or diastolic blood pressure ≥85 mm Hg)
or antihypertensive medication.
2.3. Deﬁnitions of insulin resistance and coronary artery disease
Insulin tolerance was evaluated using the homeostasis model
assessment ratio (HOMA-R, HOMA-R = fasting insulin levels × fasting
plasma glucose × 1 / 405), and insulin resistance was deﬁned as
HOMA-R N2.5[17]. We deﬁned coronary artery disease as ≥50% coro-
nary artery stenosis in each axial MDCT based on the Society of Cardio-
vascular CT guidelines [18].
2.4. Measurement of EAT volume
Cardiac MDCT was performed using a 64-slice MDCT scanner
(Aquilion 64, Toshiba, Tokyo, Japan). Nitroglycerin was administered
orally before the CT scanwas performed. A total of 51–100ml of contrast
media (Iopamidol, Bayer Co. Ltd., Leverkusen, Germany) was injected at
a ﬂow rate of 3.0–4.6 ml/s depending on the patient's body weight. TheFig. 1. Recruitment of patients who underwent MDCT at Yamagata University Hospital.
MDCT, multidetector computed tomography.region of interest was placed within the ascending and descending
aorta, and scanning was commenced when the CT density reached 250
Hounsﬁeld units at the ascending aorta or 180 Hounsﬁeld units at the
descending aorta. The scanwas performed between the tracheal bifurca-
tion and the diaphragm. Radiographic parameters were collimation
width, 0.5 mm; rotation speed, 0.4 s/rotation; tube voltage, 120 kV;
and effective tube current, 400–450 mA. Cardiac images were analyzed
at the most motionless phase of the cardiac cycle, which was most
frequently the mid-diastolic phase, with retrospective cardiac gating at
75% of the R-wave to R-wave interval.
EATwas deﬁned as the adipose tissue between the surface of the heart
and the visceral layer of the pericardium. After manually tracing a single
region of interest containing the heart and EAT on cross-sectional images,
an EAT image ranging from−200 to−30Hounsﬁeld unitswas extracted
from the heart image. The EAT area was measured every 5 mm from the
atrial appendage to the apex over the diaphragm. EAT volume was auto-
matically calculated as the sum of the EAT areas using analysis software
(ZIO station, ZIO SOFT Inc., Tokyo, Japan) [13].2.5. Statistical analysis
Data are presented as means and standard deviations (SDs). If the
data were not normally distributed, they are presented as medians
and interquartile range. Unpaired Student's t-tests and chi-square
tests were used to assess continuous and categorical variables, respec-
tively. Mann–Whitney U-tests were employed for data that were not
normally distributed. Univariate and multivariate analyses with logistic
regression were used to determine signiﬁcant predictors of insulin
resistance and coronary artery disease.Multivariate analysiswas adjust-
ed by factors thatwere found to be signiﬁcant in univariate analysis. The
optimal cutoff value for EAT volume was determined as that with the
largest sum of sensitivity plus speciﬁcity on the receiver operating char-
acteristic curve. P b 0.05 was considered statistically signiﬁcant. All
statistical analyses were performed with a standard statistical program
package (JMP version 10; SAS Institute, Cary, North Carolina).3. Results
3.1. Patient characteristics
The clinical characteristics of the 293patients enrolled in the present
study are listed in Table 1. There were 76 females (32%) and mean age
was 63 (13) years old. There were 22 (9%) current smokers and 88
(37%) patients with coronary artery disease. The median EAT volume
was 35 ml (interquartile range: 15–51), and the mean body mass
index was 22 (2) kg/m2. There were 102 (43%) patients with insulin
resistance, and they exhibited higher serum levels of high-sensitivity
C-reactive protein (hsCRP), and low-density lipoprotein cholesterol
level (LDLc), as well as higher coronary artery disease prevalence com-
pared to those without it. Furthermore, patients with insulin resistance
showed higher EAT volume and were more likely to have undergone
coronary artery bypass graft or percutaneous coronary intervention
compared with those without insulin resistance.3.2. Clinical features of patients with coronary artery disease
There were 88 (30%) patients with coronary artery disease in the
present study. Theywere younger and had higher estimated glomerular
ﬁltration rate (eGFR), higher serumhsCRP levels, and lower serumHDLc
levels compared to those without coronary artery disease (Table 2).
Moreover, patients with coronary artery disease exhibited higher EAT
volume, a greater prevalence of insulin resistance, and more plaque
lesions compared to patients without coronary artery disease.
Table 1
Baseline clinical characteristics.
All patients
(n = 239)
Insulin resistance (−)
(n = 137)
Insulin resistance (+)
(n = 102)
P value
Age, years (SD) 63 (13) 63 (13) 63 (13) 0.759
Male, n (%) 163 (68) 96 (70) 67 (66) 0.471
Current smoker, n (%) 22 (9) 13 (10) 9 (9) 0.860
Presence of CAD, n (%) 88 (37) 25 (18) 63 (62) b0.001
EAT volume, ml 35 (15–51) 22 (14–35) 34 (17–50) 0.002
Presentation proﬁle
BMI, kg/m2 (SD) 22 (2) 21 (2) 22 (2) 0.456
sBP, mm Hg (SD) 128 (22) 125 (21) 124 (22) 0.842
dBP, mm Hg (SD) 73 (12) 74 (13) 72 (11) 0.307
eGFR, ml/min/1.73 m2 (SD) 72 (22) 71 (20) 72 (22) 0.889
Blood biomarkers
hsCRP mg/dl (IQR) 0.061 (0.026–0.197) 0.052 (0.026–0.103) 0.072 (0.026–0.218) b0.001
Fasting plasma glucose, mg/dl (SD) 104 (27) 94 (15) 114 (30) b0.001
Triglyceride, mg/dl (SD) 102 (55) 106 (71) 101 (47) 0.357
HDLc, mg/dl (SD) 57 (18) 58 (18) 56 (19) 0.449
LDLc, mg/dl (SD) 103 (32) 98 (30) 109 (34) 0.010
Non-HDLc, mg/dl (SD) 118 (36) 117 (35) 120 (37) 0.518
L/H ratio (SD) 1.9 (0.8) 1.9 (0.8) 2.1 (0.8) 0.122
Total cholesterol, mg/dl (SD) 175 (40) 171 (37) 181 (44) 0.066
Characteristics of CAD
Plaque, n (%) 100 (42) 49 (36) 51 (50) 0.030
Unstable plaque, n (%) 15 (6) 5 (4) 10 (10) 0.025
Calciﬁcation, n (%) 146 (61) 82 (60) 64 (63) 0.882
Number of PCI or CABG, n (%) 50 (21) 14 (10) 36 (35) 0.012
Data are presented as mean (SD) or % unless otherwise indicated; BMI, bodymass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; dBP, diastolic blood pressure;
EAT, epicardial adipose tissue; eGFR, estimated glomerular ﬁltration rate; HDLc, high density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; IQR, interquartile range;
LDLc, lowdensity lipoprotein cholesterol; L/H ratio, low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio; PCI, percutaneous coronary intervention; sBP, systolic
blood pressure.
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The correlations between EAT and clinical parameters were exam-
ined (Table 3). EAT volume was signiﬁcantly correlated with bodyTable 2
Clinical characteristics of patients with or without coronary artery disease.
Coronary artery disease (−)
(n = 151)
Age, years (SD) 66 ± 12
Male, n (%) 101 (67)
Current smoker, n (%) 18 (12)
Presence of IR, n (%) 37 (25)
EAT volume, ml (SD) 28 (14–37)
Presentation proﬁle
BMI, kg/m2 (SD) 22 (3)
sBP, mmHg (SD) 125 (22)
dBP, mm Hg (SD) 74 (12)
eGFR, ml/min/1.73 m2 (SD) 68 (23)
Blood biomarkers
hsCRP mg/dl (IQR) 0.063 (0.025–0.151)
Fasting plasma glucose, mg/dl (SD) 101 (25)
Triglyceride, mg/dl (SD) 106 (59)
HDLc, mg/dl (SD) 60 (19)
LDLc, mg/dl (SD) 101 (32)
Non-HDLc, mg/dl (SD) 114 (35)
L/H ratio (SD) 1.7 (0.7)
Total cholesterol, mg/dl (SD) 175 (41)
Characteristics of CAD
Plaque, n (%) 37 (25)
Unstable plaque, n (%) -
Calciﬁcation, n (%) 88 (58)
Number of PCI or CABG, n (%) –
Data are presented as mean (SD) or % unless otherwise indicated; BMI, bodymass index; CABG
EAT, epicardial adipose tissue; eGFR, estimated glomerular ﬁltration rate; HDLc, high-density li
IR, insulin resistance; LDLc, low-density lipoprotein cholesterol; L/H ratio, low-density lipopro
intervention; sBP, systolic blood pressure.mass index (r = 0.351, P b 0.001) and HOMA-R (r = 0.325,
P b 0.001). Moreover, EAT volume was weakly correlated with age
(r = 0.234, P = 0.001) and levels of hsCRP levels (r = 0.156,
P = 0.025), fasting plasma glucose (r= 0.154, P= 0.017), triglycerideCoronary artery disease (+)
(n = 88)
P value
61 ± 13 0.002
62 (70) 0.568
4 (5) 0.057
65 (74) b0.001
37 (18–49) 0.007
22 (2) 0.121
123 (21) 0.424
71 (11) 0.068
75 (20) 0.032
0.087 (0.026–0.214) b0.001
110 (29) 0.016
114 (73) 0.345
53 (16) 0.010
106 (32) 0.187
122 (37) 0.085
2.1 (0.8) 0.001
175 (40) 0.957
63 (72) 0.010
15 (17) -
58 (66) 0.556
50 (57) –
, coronary artery bypass graft; CAD, coronary artery disease; dBP, diastolic blood pressure;
poprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; IQR, interquartile range;
tein cholesterol to high-density lipoprotein cholesterol ratio; PCI, percutaneous coronary
Table 3
Relationships between clinical parameters, biomarkers, and EAT.
EAT
r P value
Age 0.234 0.001
BMI 0.354 b0.001
Blood biomarkers
hsCRP 0.156 0.025
Fasting plasma glucose 0.154 0.017
Insulin 0.006 0.929
Triglyceride 0.232 0.001
HDLc −0.178 0.022
LDLc 0.256 b0.001
Non-HDLc 0.075 0.249
L/H ratio 0.048 0.460
Total cholesterol 0.193 0.010
HOMA-R 0.325 b0.001
BMI, bodymass index; EAT, epicardial adipose tissue; HDLc, high-density lipoprotein cho-
lesterol; HOMA-R, homeostasismodel assessment ratio; hsCRP, high-sensitivity C-reactive
protein; LDLc, low-density lipoprotein cholesterol; L/H ratio, low-density lipoprotein cho-
lesterol to high-density lipoprotein cholesterol ratio.
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0.256, P b 0.001), and total cholesterol (r= 0.193, P= 0.010). Howev-
er, insulin, non-HDLc, and the LDLc to HDLc ratio (L/H ratio) were not
correlated with EAT.
3.4. Predictors of insulin resistance
Univariate and multivariate analyses with logistic regression for
predicting the presence of insulin resistance are shown in Table 4.
Increased EAT volume (odds ratio 1.23, 95% conﬁdence interval
1.05–1.44) was independently associated with insulin resistance after
adjustment for age, gender, body mass index, and systolic blood
pressure.
3.5. Predictors of coronary artery disease
Univariate and multivariate analyses with logistic regression
for predicting the presence of coronary artery disease are shown in
Table 5. Increased EAT volume (odds ratio 1.20, 95% conﬁdence interval
1.07–1.36) was independently associated with coronary artery disease
after adjustment for age, gender, body mass index, and diastolic blood
pressure.Table 4
Univariate and multivariate analyses of factors predicting insulin resistance.
Univariate analysis
Unadjusted OR 95% CI of OR
Age, per 10-year increase 1.23 1.01–1.49
Gender (male) 1.72 0.94–3.14
Presentation proﬁle
BMI, per 1 SD increase 1.12 1.11–1.49
sBP, per 10 mm Hg increase 1.13 1.00–1.28
dBP, per 10 mm Hg increase 1.03 0.83–1.31
Blood biomarkers
hsCRP, per 1 SD increase 1.27 0.90–1.78
Triglyceride, per 1 SD increase 1.12 0.72–1.18
HDLc, per 1 SD decrease 1.12 0.84–1.49
LDLc, per 1 SD increase 1.21 0.91–1.17
Non-HDLc, per 1 SD increase 1.11 0.70–1.20
L/H ratio, per 0.1 increase 1.03 0.94–1.01
Total cholesterol, per 1 SD increase 1.25 0.93–1.68
EAT, per 10 ml increase 1.23 1.07–1.42
BMI, body mass index; CAD, coronary artery disease; dBP, diastolic blood pressure; EAT, epicardi
cholesterol; hsCRP, high-sensitivity C-reactive protein; LDLc, low-density lipoprotein choleste
ratio; OR, odds ratio; sBP, systolic blood pressure.
a Adjusted OR after adjustment for age, gender, body mass index, and systolic blood pressurThe receiver operating characteristic curve for EAT volume as a pre-
dictor of coronary artery disease is shown in Fig. 2. The area under the
receiver operating characteristic curve for predicting coronary artery
disease was 0.624. EAT volume ≥40 ml had a sensitivity of 56% and a
speciﬁcity of 61% for predicting coronary artery disease.
4. Discussion
In the present study, we demonstrated that increased EAT volume
was associated with the presence of insulin resistance and coronary
artery disease in non-obese Japanese subjects without metabolic syn-
drome. The cut-off value of EAT volume to predict coronary artery dis-
ease was ≥40 ml in non-obese subjects without metabolic syndrome.
The worldwide prevalence rates of obesity and overabundance of
visceral fat are increasing. The World Health Organization (WHO) and
the U.S. National Institutes of Health deﬁned obesity as body mass
index ≥30 kg/m2 [1]. However, the prevalence of obesity is markedly
lower in Japan (2–3%), in contrast to 10–20% in Western populations
[7]. Therefore, the Japan Society for the Study of Obesity has deﬁned
obesity as body mass index ≥25 kg/m2 [6]. Many reports have shown
that excess visceral fat is more closely related the obesity-linked
diseases (i.e., hypertension, dyslipidemia, gout, and coronary artery
disease) than obesity itself in Japan [3,19,20]. Our data showed that
increased EAT volumewas associatedwith the presence of insulin resis-
tance and coronary artery disease even in non-obese subjects. These
results were consistent with previous reports [3,19,20].
EAT volumewas also reported to be signiﬁcantly related to coronary
artery disease in subjects with metabolic syndrome [21]. EAT produces
various cytokines and promotes a catabolic state due to chronic adipose
tissue inﬂammation and insulin resistance in individualswithmetabolic
syndrome [22]. In the present study, we showed that increased EAT
volume was associated with the presence of insulin resistance and cor-
onary artery disease in non-obese subjectswithoutmetabolic syndrome
independent of bodymass index. These data suggest that there is a caus-
al relationship between increased EAT and coronary artery disease.
The mechanism by which EAT impairs insulin signaling and
promotes coronary artery disease is thought to be associated with in-
creased levels of inﬂammatory mediators (i.e., tumor necrosis factor-
alpha, interleukin-6, and plasminogen activator inhibitor-1) induced
by EAT [23,24].We previously demonstrated that increased EAT volume
and adipocyte sizewere associatedwith impaired adiponectin secretion
in pericardial ﬂuid, which may facilitate the development of coronary
artery disease in non-obese subjects [13]. EAT volume was weakly butMultivariate analysis
P value Adjusted ORa 95% CI of OR P value
0.036 1.05 0.85–1.32 0.635
0.077 1.61 0.85–3.06 0.147
b0.001 1.39 1.26–1.50 0.003
0.049 1.08 0.95–1.23 0.236
0.767
0.170
0.534
0.466
0.188
0.516
0.124
0.145
0.003 1.23 1.05–1.44 0.010
al adipose tissue; eGFR, estimated glomerular ﬁltration rate; HDLc, high-density lipoprotein
rol; L/H ratio, low-density lipoprotein cholesterol to high-density lipoprotein cholesterol
e.
Table 5
Univariate and multivariate analyses of factors predicting coronary artery disease.
Univariate analysis Multivariate analysis
Unadjusted OR 95% CI of OR P value Adjusted ORa 95% CI of OR P value
Age, per 10-year increase 1.01 0.83–1.18 0.930 1.00 0.82–1.22 0.967
Gender (male) 1.17 0.71–2.12 0.472 1.16 0.64–2.10 0.636
Presentation proﬁle
BMI, per 1 SD increase 1.04 0.80–1.34 0.775
sBP, per 10 mm Hg increase 1.07 0.84–1.04 0.225
dBP, per 10 mm Hg increase 1.23 1.00–1.54 0.050 1.21 0.84–1.50 0.087
Blood biomarkers
hsCRP, per 1 SD increase 1.13 0.85–1.49 0.393
Triglyceride, per 1 SD increase 1.06 0.72–1.18 0.571
HDLc, per 1 SD decrease 1.06 0.81–1.36 0.703
LDLc, per 1 SD increase 1.03 0.80–1.33 0.827
Non-HDLc, per 1 SD increase 1.24 0.31–13.07 0.087
L/H ratio, per 0.1 increase 1.06 1.02–1.10 0.002 1.06 1.02–1.10 0.003
Total cholesterol, per 1 SD increase 1.06 0.72–1.18 0.570
EAT, per 10 ml increase 1.25 1.15–1.46 0.009 1.20 1.07–1.36 0.047
BMI, body mass index; dBP, diastolic blood pressure; eGFR, estimated glomerular ﬁltration rate; EAT, epicardial adipose tissue; HDLc, high-density lipoprotein cholesterol; hsCRP, high-
sensitivity C-reactive protein; IR, insulin resistance; LDLc, low-density lipoprotein cholesterol; L/H ratio, low-density lipoprotein cholesterol to high-density lipoprotein cholesterol
ratio; OR, odds ratio; sBP, systolic blood pressure.
a Adjusted OR after adjustment for age, gender, body mass index, and diastolic blood pressure.
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Increased EAT volume may be associated with adipocytokine secretion,
which induces insulin resistance and coronary artery disease even in
non-obese subjects without metabolic syndrome.4.1. Study limitations
There were several limitations in the present study. First, we did not
measure adipocytokine level. Because EAT volume was weakly but sig-
niﬁcantly correlated with serum hsCRP in this study, EAT-released
adipocytokines may promote inﬂammation. Second, this was a cross-
sectional study and therefore could not identify a cause–effect relation-
ship. Future prospective study about the impact of EAT volume on
cardiovascular events is needed. Thirdly, sensitivity and speciﬁcity of
EAT for predicting coronary artery disease were not so high. It was be-
causewe enrolled not only the patients whowere suspectedwith coro-
nary artery disease but also those who were not. Future prospective
study with patients who were suspected with coronary artery disease
only is needed.se
n
si
tiv
ity
0
0.2
0.4
0.6
0.8
1
0 0.2 0.4 0.6 0.8 1
AUC=0.624
40 ml
1-specificity
Fig. 2. The receiver operating characteristic curves for EAT volume to predict coronary
artery disease in non-obese subjects. The receiver operating characteristic curves and
area under the curve for coronary artery disease (cut-off value = 40 ml, area under the
curve = 0.624). EAT, epicardial adipose tissue.4.2. Conclusions
In conclusion, increased EAT volume was associated with the pres-
ence of insulin resistance and coronary artery disease in non-obese sub-
jects without metabolic syndrome. These results suggest that increased
EAT may play a role in coronary artery disease through insulin resis-
tance in lean subjects who do not have metabolic syndrome.
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